



Republic of the Philippines
Department of Health
OFFICE OF THE SECRETARY

July 26, 2022

DEPARTMENT MEMORANDUM

No. 2022 - 0206-A

TO: ALL UNDERSECRETARIES AND ASSISTANT SECRETARIES; DIRECTORS OF BUREAUS, SERVICES AND CENTERS FOR HEALTH DEVELOPMENT; MINISTER OF HEALTH – BANGSAMORO AUTONOMOUS REGION IN MUSLIM MINDANAO; EXECUTIVE DIRECTORS OF SPECIALTY HOSPITALS AND NATIONAL NUTRITION COUNCIL; CHIEFS OF MEDICAL CENTERS, HOSPITALS, SANITARIA AND INSTITUTES; PRIVATE SECTOR PARTNERS; ALL LOCAL GOVERNMENT UNITS; AND OTHERS CONCERNED

SUBJECT: Amendment to the Department Memorandum No. 2022-0206: “Interim Operational Guidelines on the Administration of 2nd COVID-19 Vaccine Booster Doses to Senior Citizens and Frontline Healthcare Workers ages 18 years Old and Above”

On July 25, 2022, the Philippine Food and Drug Administration (FDA) expanded the Emergency Use Authorization (EUA) of certain COVID-19 vaccine brands to allow for their use as a second booster dose for individuals 50 years old and above and adults 18 to 49 years old with comorbidities. On July 26, 2022, the Health Technology Assessment Council (HTAC), after a thorough and expert review of the best available evidence, released their recommendation that the mRNA vaccines, Pfizer and Moderna, can be used as a second booster for individuals aged 50 years and older and in individuals aged 18 to 49 years old with comorbidities.

With this, **Section IV. A. of Department Memorandum No. 2022-0206** dated May 18, 2022, otherwise known as, “Interim Operational Guidelines on the Administration of 2nd COVID-19 Vaccine Booster Doses to Senior Citizens and Frontline Healthcare Workers ages 18 years Old and Above” is hereby amended to **expand the provision of second booster doses** to include the following:

- a. **All individuals 50 years old and above; and**
- b. **Adults 18 to 49 years old with comorbidities.**


The second booster shall be administered at least 4 months after the 3rd dose or 1st booster. The vaccines to be inoculated shall include only the following COVID-19 vaccines granted with FDA EUA and HTAC recommendation: Tozinameran (Pfizer) and Spikevax (Moderna).

The decision to administer a second booster dose to patients with comorbidities shall be based on the **risk-benefit assessment** by the medical screener at the vaccination site. All implementing units shall be reminded to follow the vaccination process stipulated in the **Administrative Order No. 2022-0005**, otherwise known as the “Omnibus Guidelines on the

Implementation of the National Deployment and Vaccination Plan for COVID-19 vaccines,”
and other relevant issuances.

All the provisions of Department Memorandum No. 2022-0206 dated May 18, 2022 not
affected by this amendment shall remain valid and in effect.

By Authority of the Secretary of Health:



NESTOR F. SANTIAGO JR., MD, MPH, MHA, MSA, CESO II
Assistant Secretary of Health
Field Implementation and Coordination Team
Incident Manager - National Vaccination Operations Center